Business Wire

TAKEDA-PHARMACEUTICAL

27.1.2021 11:02:10 CET | Business Wire | Press release

Share
Takeda Achieved Carbon Neutrality in 2020

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it achieved carbon neutrality in its value chain for its fiscal year 2019. This achievement was delivered by a continued focus on internal energy conservation measures, procurement of green energy, and investment in renewable energy certificates and high-quality, verified carbon offsets. These actions collectively address 100 percent of Takeda’s fiscal year 2019 scope 1, 2, and 3 emissions1 and represent a significant milestone in Takeda’s sustainability journey.

“This important milestone underscores our commitment to environmental sustainability as we recognize that climate change poses a risk to human health, including the spread of some of the same infectious diseases we’re working to eradicate,” said Christophe Weber, Takeda president and chief executive officer. “As a global, purpose-driven company celebrating our 240-year anniversary this summer, I am proud of our achievement, but we know much more work needs to be done. We remain committed to using our size and scale to help mitigate climate change and to ensure we can continue to make a positive impact on patients, our people and the planet.”

One of the ways Takeda achieved this milestone is through its investment in more than 30 renewable energy and carbon offset projects across 12 countries. These projects support the use of wind and solar energy, clean water availability, forest conservation and the preservation of biodiversity. The activities collectively address 15 out of 17 of the United Nations’ Sustainable Development Goals. They support local communities, while promoting a more sustainable future. All carbon offsets were required to meet rigorous evaluation criteria, including additionality, measurability, transparency, registration and third-party verification, among others.

Projects supported include:

  • Clean drinking water in Malawi – providing safe drinking water to communities by creating new boreholes and repairing damaged ones, resulting in the reduced use of firewood for boiling and purifying water
  • Working Woodlands Program – preserving more than 8,600 acres in the northeastern corner of Tennessee, U.S., as a privately held park, encouraging recreation-based tourism in a lower-income region of the United States
  • Forest management in Japan – supporting natural carbon sinks and local air quality through sustainable forestry management practices in Japan
  • Solar cookstoves in China – helping to improve indoor air quality by investing in the installation of solar cookers to replace coal for cooking and hot water needs for rural farmers in remote areas of China
  • Solar energy in India – supporting the development of solar lighting and thermal water heating to replace fossil fuel usage throughout different states in India

Building on today’s milestone, Takeda remains committed to eliminating greenhouse gas emissions from its company-wide operations. Specifically, Takeda aims to reduce 40 percent of its emissions from its operations by 2025 and has committed to being carbon zero by 2040. To achieve its climate-related goals, a company-wide, cross-divisional program has been established to increase renewable energy usage and drive energy efficiency. Takeda is also looking beyond its own operations and is working with suppliers to help them to establish science-based reduction targets and reduce greenhouse gas emissions.

As a science-driven organization, Takeda’s climate change commitments are aligned with current climate science. In 2020, the Science-Based Targets initiative (SBTi) recognized Takeda’s goals as being consistent with reductions required to limit the rise in global temperature to 1.5°C above pre-industrial levels. Takeda is also proud to have earned a spot on CDP’s ‘A List’ for climate change leadership in 2020 as well as being named to Corporate Knights Global 100 Most Sustainable Corporations in the World (Global 100) for the sixth consecutive year.

For more information on Takeda’s commitment to environmental sustainability, visit:
Takeda environment website
Sustainability Value Report 2020

About Takeda Pharmaceutical Company Limited

Takeda Pharmaceutical Company Limited (TSE: 4502/NYSE: TAK ) is a global, values-based, R&D-driven biopharmaceutical leader headquartered in Japan, committed to discover and deliver life-transforming treatments, guided by our commitment to patients, our people and the planet. Takeda focuses its R&D efforts on four therapeutic areas: Oncology, Rare Genetic and Hematology, Neuroscience, and Gastroenterology (GI). We also make targeted R&D investments in Plasma-Derived Therapies and Vaccines. We are focusing on developing highly innovative medicines that contribute to making a difference in people’s lives by advancing the frontier of new treatment options and leveraging our enhanced collaborative R&D engine and capabilities to create a robust, modality-diverse pipeline. Our employees are committed to improving quality of life for patients and to working with our partners in healthcare in approximately 80 countries. For more information, visit https://www.takeda.com .

1 Scope 1 emissions are direct emissions from owned or controlled sources such as onsite fuel combustion, company-owned vehicles, and in-equipment in our facilities.
Scope 2 emissions are indirect greenhouse gas emissions resulting from purchased and consumed electricity, third party steam and/or chilled water supplied to our facilities.
Scope 3 emissions are all other indirect emissions that occur in our value chain, including goods and services provided by suppliers, business travel, employee commuting, and landfill waste disposal.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

FPT Launches Flezi Foundry™, Advancing AI-Augmented Delivery for Global Enterprises22.5.2026 10:11:00 CEST | Press release

Global IT corporation FPT announced the launch of Flezi Foundry™ (FPT Digital Foundry™), an AI-augmented delivery platform for software development and IT operations. Built around a governed Service-as-a-Software model, the platform combines autonomous AI agents, human expert oversight, secure infrastructure, and outcome-based delivery mechanisms to help enterprises modernize technology delivery as AI agents become part of software engineering and IT operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521235556/en/ Flezi Foundry applies Agentic Engineering, a structured delivery approach for software development and IT operations. The model brings AI agents into delivery workflows with human supervision, governance, transparency, and performance measurement built into the process. Flezi Foundry operates through two service modes: Agentic Development Lifecycle (ADLC) supports software development by using specialize

Boomi Named One of The Sunday Times Best Places to Work 202622.5.2026 08:00:00 CEST | Press release

Employee-led recognition places Boomi among the UK's top medium-sized employers, with a flight risk of just 3% against a technology sector average of 42% Boomi achieves an average employee happiness score of 86%, rated Excellent across all six dimensions of WorkL's workplace framework Flight risk of just 3%, compared to a technology sector average of 42%, reflecting exceptional levels of employee loyalty Rated Excellent for Diversity and Inclusion and Confidence in Management Boomi, the data activation company for AI, has today been named one of The Sunday Times Best Places to Work 2026 in the Medium Organisation category. The prestigious annual list, produced by The Sunday Times in partnership with global workplace analytics company WorkL, recognises the UK's finest employers based entirely on direct employee feedback, making it one of the most credible and transparent employer benchmarks in the country. This press release features multimedia. View the full release here: https://www.b

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye